Valvular & structural heart diseaseCohort study
Tricuspid Regurgitation Disease Stages and Treatment Outcomes After Transcatheter Tricuspid Valve Repair
- Prospective registry cohort study
- external validation cohort
Authors' conclusion
Compared to medically treated controls, T-TEER was associated with 1-year survival at intermediate stage disease but not at early or advanced disease stages.
Study context
- Population
- Patients with significant tricuspid regurgitation (TR) in the EuroTR registry, grouped into early, intermediate and advanced disease stage (LV and RV function, renal function, natriuretic peptide levels)
- Participants
- 1,885 patients
- Exposure
- Tricuspid transcatheter edge-to-edge repair (T-TEER) vs conservative treatment, by TR disease stage
- T-TEERn = 1,300
- Conservativen = 585reference
- Outcome
- Mortality
- Follow-up
- 1 year
Main finding
As reported in the abstract
1-year mortality by TR disease stage
T-TEER vs ConservativeHazard ratio (95% CI)P value
early stage
0.78(0.34–1.80)
P = 0.54advanced stage
1.06(0.71–1.60)
P = 0.78Observational data: associations, not effects.
Further findings
Disease stage distribution
- Early stage
- 395 (21%)
- Intermediate stage
- 1,173 (62%)
- Advanced stage
- 317 (17%)
Original publication
Tricuspid Regurgitation Disease Stages and Treatment Outcomes After Transcatheter Tricuspid Valve Repair. JACC Cardiovasc Interv. Published 10 February 2025. doi:10.1016/j.jcin.2024.10.034
Summarised from the published abstract; every number is checked against it